Benefits of Using Dapsone in Patients Hospitalized with COVID-19

Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main cause of death. We have earlier reported results of the addition of dapsone in this population to the standard of care. We now report...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanwar, Badar A., Khattak, Asif, Balentine, Jenny, Lee, Jong Hoon, Kast, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879930/
https://www.ncbi.nlm.nih.gov/pubmed/35214654
http://dx.doi.org/10.3390/vaccines10020195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879930/
https://www.ncbi.nlm.nih.gov/pubmed/35214654
http://dx.doi.org/10.3390/vaccines10020195

Ejemplares similares